

Visible-light-induced deoxygenative C2-sulfonylation of quinoline *N*-oxides with sulfinic acids

Long-Yong Xie^a, Tai-Gang Fang^a, Jia-Xi Tan^{a,b}, Bo Zhang^c, Zhong Cao^c, Li-Hua Yang^a
and Wei-Min He^{*a}

^aDepartment of Chemistry, Hunan University of Science and Engineering, Yongzhou 425100,
China

^bHunan Provincial Key Laboratory of Materials Protection for Electric Power and Transportation,
Changsha University of Science and Technology, Changsha, 410114, China

^cSchool of Chemistry and Chemical Engineering, Hunan University of Science and Technology,
Xiangtan 411201, China

E-mail: weiminhe2016@yeah.net

Table of Content


1. General information	S2
2. Experimental Section	S2
3. Characterization data of products	S8
4. References	S18
5. ¹H and ¹³C NMR spectra of products	S19

1. General information

Unless otherwise specified, all reagents and solvents were obtained from commercial suppliers and used without further purification. All reagents were weighed and handled in air at room temperature. ^1H NMR spectra were recorded at 400 MHz and ^{13}C NMR spectra were recorded at 100 MHz by using a Bruker Avance 400 spectrometer. Chemical shifts were calibrated using residual undeuterated solvent as an internal reference (^1H NMR: CDCl_3 7.26 ppm, ^{13}C NMR: CDCl_3 77.0 ppm). The following abbreviations were used to describe peak splitting patterns when appropriate: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, brs = broad singlet. Mass spectra were performed on a spectrometer operating on ESI-TOF. There is about 3.0 cm distance between the reactor and LEDs.

2. Experimental Section

2.1 General procedure for the synthesis of 2-Sulfonylquinolines



To a solution of sulfinic acid (0.4 mmol), and Na₂-EosinY (0.004 mmol) in acetone/H₂O (1 mL, $v_1/v_2=1.5/1$) was added quinoline *N*-oxide (0.2 mmol). The reaction mixture was open to the air and stirred at room temperature under the irradiation of 5W blue LED lamps for about 12h. After completion of the reaction, the resulting mixture was extracted with EtOAc and the solvent was then removed under vacuum. The residue was purified by flash column chromatography using a mixture of petroleum ether and ethyl acetate as eluent to give the desired product 3.

2.2 Preparation of 2-*d*₁-Quinoline-*N*-Oxide

D₂O (1.5 mL), NaOH (200 mg, 5 mmol), quinoline-*N*-oxide (258 mg, 2.0 mmol) were weighed into 30-mL pressure tube sealed with rubber plugs. The reaction mixture was stirred at 100 °C for overnight. After cooling to room temperature, the mixture was then extracted with EtOAc (3 x 10 mL). The combined organic phase was washed with saturated NaCl solution (3 x 5 mL), dried over MgSO₄, and filtered. EtOAc was removed under reduced pressure to obtain the crude product 2-*d*₁-quinoline-*N*-Oxide. It was further purified by flash column chromatography and percentage of *d* - incorporation was determined by ^1H NMR. Peak areas at 8.74 ppm and 8.53 ppm were compared to obtain the deuterium incorporation. Deuterium incorporation was detected to be 92% by ^1H NMR (see ^1H spectrum, Figure S1).





Figure S1

2.3 KIE Experiment



To a solution of sulfonic acid (0.4 mmol), and Na₂-EosinY (0.004 mmol) in acetone/H₂O (1 mL, v₁/v₂=1.5/1) was added Quinoline *N*-oxide **1a** and 2-*d*₁-quinoline *N*-oxide **[D₁]-1a** (1:1, totally 0.2 mmol, deuteration ratio has been calculated). The reaction mixture was open to the air and stirred at room temperature under the irradiation of 5W blue LED lamps for 2h, then the residual starting material (mixture of 2-*d*₁-quinoline-*N*-oxide and quinoline -*N*-oxide) was recovered by column chromatography on silica gel (200-300 mesh), which was characterized by ¹H NMR spectroscopy (Figure S2). Peak areas at 8.74 ppm and 8.52 ppm were compared to give the ratio (0.56:0.44) of 2-*d*₁-quinoline *N*-oxide to quinoline *N*-oxide in residual material. k_H/k_D was calculated using the following expression¹:

$$K_H/K_D = \frac{M / 2 - 0.44m}{M / 2 - 0.56m}$$

M, m represent the amount of 2-d₁-quinoline N-oxide and quinoline N-oxide in reaction starting material and residual material, respectively. Here, M = 29, m = 14, which corresponds to $k_H/k_D = 1.25$.






Figure S2

2.4 Gram-scale synthesis of **3aa**



To a solution of 4-methylbenzenesulfonic acid (1.56 g, 10 mmol), and Na₂-EosinY (69.1 mg, 0.1 mmol) in acetone/H₂O (25 mL, v₁/v₂=1.5/1) was added quinoline N-oxide (0.73 g, 5 mmol). The reaction mixture was open to the air and stirred at room temperature under the irradiation of 5W blue LED lamps for about 12h. After completion of the reaction, the resulting mixture was extracted with EtOAc (15 mL × 3) and the solvent was then removed under vacuum. The residue was purified by flash column chromatography using a mixture of petroleum ether and ethyl acetate as eluent to give 1.12 gram of **3aa**, yield 79%.

2.5 Synthesis of sulfonated cloquintocet-mexyl (**3sa**)



A solution of clointocet-mexyl **4s** (0.34 g, 1.0 mmol) in DCM (10 mL) was stirred at 0 °C for 5 min. Then *m*-CPBA (3-chloroperbenzoic acid, 1.5 mmol) was added to the solution through several times. The mixture was stirred at 25 °C for 12 h and a saturated aqueous NaHCO₃ solution (10 mL) was added. The resulting solution was extracted with DCM (10 mL × 2). Then it was dried by Na₂SO₄ and concentrated under reduced pressure to obtain the crude product clointocet-mexyl *N*-oxide and used without further purification.

The above-synthesized crude product clointocet-mexyl *N*-oxide was added to a solution of 4-methylbenzenesulfonic acid (0.31 g, 2 mmol), and Na₂-EosinY (13.8 mg, 0.02 mmol) in acetone/H₂O (5 mL, *v*₁/*v*₂ = 1.5/1). The reaction mixture was open to the air and stirred at room temperature under the irradiation of 5W blue LED lamps for about 12 h. After completion of the reaction, the resulting mixture was extracted with EtOAc (10 mL × 3) and the solvent was then removed under vacuum. The residue was purified by flash column chromatography using a mixture of petroleum ether and ethyl acetate as eluent to give 0.31 gram of **3sa**, yield 63%.

2.6 Cyclic voltammetry measurement

CV measurements were performed on a CHI-660B workstation (Shanghai Chenhua Instruments Co., China) with the three-electrode system using a glassy carbon working electrode, a platinum wire counter electrode, an Ag/AgCl as a reference electrode and TBATFB 0.1 M as supporting electrolyte. The potentials were achieved relative to the Fc/Fc⁺ redox couple with ferrocene as internal standard. The measurements were carried out as follows: a 0.1 M solution of TBATFB in acetone/H₂O (1.5:1) was added to the measuring cell and the solution was degassed by argon purge for 5 min. After recording the baseline the electroactive compound was added (0.01 M) and the solution was again degassed a stream of argon for 5 min. The cyclic voltammogram was recorded with one to three scans. Afterwards ferrocene (2.20 mg, 12.0 μmol) was added to the solution which was again degassed by argon purge for 5 min and the final measurement was performed with three scans.




Figure S3. Cyclic voltammogram of 4-methylbenzenesulfinic acid (**2a**) in acetone/H₂O (1.5:1) under argon (scan direction indicated by black arrow). The irreversible peak at -1.35 V is the reduction of **2a**.






Figure S4. Cyclic voltammogram of Na₂·eosin Y in acetone/H₂O (1.5:1) under argon (scan direction indicated by black arrow). The irreversible peak at +0.91 V is the oxidation of Na₂·eosin Y.

2.7 Possible mechanism with TBHP as the oxidant




3. Characterization data of products

2-tosylquinoline (3aa)²




¹H NMR (400 MHz, CDCl₃): δ = 8.36 (d, *J* = 8.8 Hz, 1 H), 8.20 – 8.16 (m, 2 H), 8.03 – 8.00 (m, 2 H), 7.86 (d, *J* = 8.4 Hz, 1 H), 7.79 – 7.75 (m, 1 H), 7.66 – 7.63 (m, 1 H), 7.32 (d, *J* = 8.0 Hz, 2 H), 2.39 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 158.3, 147.4, 144.8, 138.7, 136.1, 130.9, 130.3, 129.7, 129.1, 129.0, 128.7, 127.6, 117.6, 21.6.

3-methyl-2-tosylquinoline (3ba)³




¹H NMR (400 MHz, CDCl₃): δ = 8.03 (s, 1 H), 7.94 – 7.90 (m, 3 H), 7.74 – 7.72 (m, 1 H), 7.65 – 7.60 (m, 1 H), 7.58 – 7.54 (m, 1 H), 7.34 (d, *J* = 8.0 Hz, 2 H), 2.84 (s, 3 H), 2.44 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 156.9, 144.6, 144.4, 139.8, 135.7, 129.8, 129.6, 129.3, 129.3, 129.0, 128.9, 128.4, 126.6, 21.6, 18.8.

4-methyl-2-tosylquinoline (3ca)⁴




¹H NMR (400 MHz, CDCl₃): δ = 8.15 (dd, *J*₁ = 8.8 Hz, *J*₂ = 0.8 Hz, 1 H), 8.02 – 7.98 (m, 4 H), 7.76 – 7.72 (m, 1 H), 7.66 – 7.62 (m, 1 H), 7.31 (d, *J* = 7.6 Hz, 2 H), 2.77 (s, 3 H), 2.38 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 157.9, 147.8, 147.2, 144.6, 136.2, 131.0, 130.4, 129.7, 128.9, 128.8, 128.7, 123.7, 118.0, 21.6, 19.1.

5-methyl-2-tosylquinoline (3da)⁵




¹H NMR (400 MHz, CDCl₃): δ = 8.51 (dd, *J*₁ = 8.8 Hz, *J*₂ = 0.8 Hz, 1 H), 8.20 (d, *J* = 8.4 Hz, 1 H), 8.01 (d, *J* = 8.0 Hz, 2 H), 8.02 – 8.00 (m, 3 H), 7.66 – 7.62 (m, 1 H), 7.49 – 7.44 (m, 1 H), 7.31 (d, *J* = 8.4 Hz, 2 H), 2.68 (s, 3 H), 2.39 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 157.8, 147.8, 144.7, 136.2, 135.1, 134.7, 130.6, 129.7, 129.4, 129.0, 128.6, 128.2, 117.2, 21.6, 18.6.

6-methyl-2-tosylquinoline (3ea)⁶




^1H NMR (400 MHz, CDCl_3): δ = 8.25 (d, J = 8.4 Hz, 1 H), 8.14 (d, J = 8.4 Hz, 1 H), 8.06 (d, J = 8.4 Hz, 1 H), 8.01 (d, J = 8.0 Hz, 2 H), 7.62 – 7.59 (m, 2 H), 7.32 (d, J = 8.0 Hz, 2 H), 2.54 (s, 3 H), 2.39 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 157.4, 146.1, 144.6, 139.6, 137.7, 136.3, 133.3, 130.0, 129.7, 129.0, 128.9, 126.4, 117.7, 21.8, 21.6.

7-methyl-2-tosylquinoline (3fa)⁷




^1H NMR (400 MHz, CDCl_3): δ = 8.30 (d, J = 8.8 Hz, 1 H), 8.12 (d, J = 8.8 Hz, 1 H), 8.01 (d, J = 8.4 Hz, 2 H), 7.95 (s, 1 H), 7.75 (d, J = 8.4 Hz, 1 H), 7.47 (d, J = 8.0 Hz, 1 H), 7.32 (d, J = 8.0 Hz, 2 H), 2.54 (s, 3 H), 2.39 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 158.2, 147.7, 144.7, 141.6, 138.2, 136.2, 131.5, 129.7, 129.2, 129.0, 127.2, 126.9, 116.8, 21.8, 21.6.

8-methyl-2-tosylquinoline (3ga)²




^1H NMR (400 MHz, CDCl_3): δ = 8.30 (d, J = 8.8 Hz, 1 H), 8.17 (d, J = 8.4 Hz, 1 H), 8.06 – 8.04 (m, 2 H), 7.65 (d, J = 8.0 Hz, 1 H), 7.56 – 7.54 (m, 1 H), 7.50 – 7.46 (m, 1 H), 7.32 (d, J = 8.0 Hz, 2 H), 2.66 (s, 3 H), 2.39 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 157.1, 146.2, 144.6, 138.6, 135.8, 130.8, 129.4, 129.2, 128.8, 128.7, 128.7, 125.4, 116.6, 21.5, 17.4.

6-methoxy-2-tosylquinoline (3ha)³




^1H NMR (400 MHz, CDCl_3): δ = 8.21 (d, J = 8.4 Hz, 1 H), 8.14 (d, J = 8.4 Hz, 1 H), 8.05 (d, J = 9.2 Hz, 1 H), 8.00 (d, J = 8.4 Hz, 2 H), 7.43 – 7.40 (m, 1 H), 7.32 (d, J = 8.0 Hz, 2 H), 7.08 (d, J = 2.8 Hz, 1 H), 3.94 (s, 3 H), 2.39 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 159.8, 155.7, 144.6, 143.6, 136.8, 136.5, 131.8, 130.4, 129.7, 128.9, 124.2, 118.2, 104.5, 55.7, 21.6.

6-fluoro-2-tosylquinoline (3ia)³




^1H NMR (400 MHz, CDCl_3): δ = 8.30 (d, J = 8.8 Hz, 1 H), 8.19 – 8.12 (m, 2 H), 7.99 (d, J = 8.0 Hz, 2 H), 7.54 – 7.44 (m, 2 H), 7.31 (d, J = 8.0 Hz, 2 H), 2.37 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 161.7 ($J_{\text{C-F}}$ = 251.6 Hz), 157.7 ($J_{\text{C-F}}$ = 3.6 Hz), 144.8, 144.3, 138.0 ($J_{\text{C-F}}$ = 5.8 Hz), 135.8, 132.9 ($J_{\text{C-F}}$ = 9.5 Hz), 129.7, 129.6, 128.9, 121.5 ($J_{\text{C-F}}$ = 26.3 Hz), 118.3, 110.7 ($J_{\text{C-F}}$ = 21.9 Hz), 21.5; ^{19}F NMR (376 MHz, CDCl_3): δ = - 108.3.

6-chloro-2-tosylquinoline (3ja)²




^1H NMR (400 MHz, CDCl_3): δ = 8.28 (d, J = 8.4 Hz, 1 H), 8.20 (d, J = 8.4 Hz, 1 H), 8.09 (d, J = 9.2 Hz, 1 H), 8.00 (d, J = 8.4 Hz, 2 H), 7.85 (d, J = 3.0 Hz, 1 H), 7.70 (dd, J_1 = 9.2 Hz, J_2 = 2.0 Hz, 1 H), 7.33 (d, J = 8.0 Hz, 2 H), 2.40 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 158.6, 145.7, 145.0, 137.7, 135.8, 135.2, 132.0, 131.9, 129.8, 129.3, 129.1, 126.3, 118.6, 21.6.

4-chloro-2-tosylquinoline (3ka)⁸




^1H NMR (400 MHz, CDCl_3): δ = 8.28 (s, 1 H), 8.26 (dd, J_1 = 8.4 Hz, J_2 = 0.8 Hz, 1 H), 8.20 – 8.18 (m, 1 H), 8.03 – 8.00 (m, 2 H), 7.86 – 7.81 (m, 1 H), 7.77 – 7.73 (m, 1 H), 7.34 (d, J = 8.0 Hz, 2 H), 2.41 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 158.2, 148.1, 145.2, 145.2, 135.6, 131.7, 130.8, 130.1, 129.9, 129.2, 127.0, 124.2, 117.9, 21.7.

3-bromo-2-tosylquinoline (3la)⁴




^1H NMR (400 MHz, CDCl_3): δ = 8.51 (s, 1 H), 7.99 – 7.95 (m, 3 H), 7.78 – 7.73 (m, 2 H), 7.67 (d, J = 8.0 Hz, 1 H), 7.36 (d, J = 8.4 Hz, 2 H), 2.46 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 154.4, 144.9, 144.4, 142.9, 134.9, 131.0, 130.2, 130.0, 129.8, 129.7, 129.4, 126.5, 111.4, 21.7.

5-bromo-2-tosylquinoline (3ma)⁹




^1H NMR (400 MHz, CDCl_3): δ = 8.75 (dd, J_1 = 8.8 Hz, J_2 = 0.4 Hz, 1 H), 8.28 (d, J = 8.8 Hz, 1 H), 8.15 – 8.13 (m, 1 H), 8.02 – 8.00 (m, 2 H), 7.93 – 7.91 (m, 1 H), 7.65 – 7.61 (m, 1 H), 7.34 (d, J = 8.0 Hz, 2 H), 2.41 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 159.2, 148.1, 145.0, 138.5, 135.7, 132.7, 131.1, 130.3, 129.8, 129.1, 128.7, 121.8, 118.8, 21.7.

6-bromo-2-tosylquinoline (3na)³




^1H NMR (400 MHz, CDCl_3): δ = 8.27 (d, J = 8.4 Hz, 1 H), 8.21 (d, J = 8.4 Hz, 1 H), 8.04 – 7.99 (m, 4 H), 7.83 (dd, J_1 = 9.2 Hz, J_2 = 2.0 Hz, 1 H), 7.34 (d, J = 8.0 Hz, 2 H), 2.41 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 158.7, 145.9, 145.0, 137.6, 135.7, 134.5, 131.9, 129.8, 129.7, 129.1, 123.5, 118.6, 21.7.

8-bromo-2-tosylquinoline (3oa)⁹




^1H NMR (400 MHz, CDCl_3): δ = 8.36 (d, J = 8.8 Hz, 1 H), 8.25 (d, J = 8.4 Hz, 1 H), 8.13 (d, J = 8.4 Hz, 2 H), 8.07 (d, J = 7.6 Hz, 1 H), 7.82 (d, J = 8.4 Hz, 1 H), 7.47 (t, J = 8.0 Hz, 1 H), 7.36 (d, J = 8.0 Hz, 2 H), 2.42 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 159.4, 145.0, 144.4, 139.2, 135.2, 134.5, 129.9, 129.8, 129.5, 129.3, 127.4, 125.8, 117.7, 21.7.

8-(4-bromophenyl)-2-tosylquinoline (3pa)




^1H NMR (400 MHz, CDCl_3): δ = 8.42 (d, J = 8.4 Hz, 1 H), 8.24 (d, J = 8.4 Hz, 1 H), 7.87 – 7.85 (m, 3 H), 7.75 (dd, J_1 = 7.2 Hz, J_2 = 1.2 Hz, 1 H), 7.67 (t, J = 7.6 Hz, 1 H), 7.47 – 7.45 (m, 2 H), 7.29 – 7.27 (m, 4 H), 2.47 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 158.5, 144.8, 144.2, 139.9, 139.0, 136.8, 134.8, 132.2, 131.1, 130.7, 129.6, 129.4, 129.2, 128.8, 127.6, 121.6, 116.6, 21.7; IR (in KBr): ν = 3416, 1578, 1489, 1298, 1135, 1010, 968, 821, 681 (cm^{-1}); HRMS (ESI) m/z calcd. for $\text{C}_{22}\text{H}_{17}\text{BrNO}_2\text{S}[\text{M}+\text{H}]^+$: 438.0158, found 438.0163.

6-bromo-4-methoxy-2-tosylquinoline (3qa)




^1H NMR (400 MHz, CDCl_3): δ = 8.36 (d, J = 2.0 Hz, 1 H), 8.00 (d, J = 8.0 Hz, 2 H), 7.93 (d, J = 9.2 Hz, 1 H), 7.80 – 7.77 (m, 1 H), 7.59 (s, 1 H), 7.34 (d, J = 8.0 Hz, 2 H), 4.15 (s, 3 H), 2.42 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 163.4, 160.0, 146.9, 144.9, 135.7, 134.6, 131.5, 129.8, 129.1, 124.6, 122.7, 122.4, 97.6, 56.7, 21.7; IR (in KBr): ν = 3419, 2930, 1571, 1418, 1327, 819, 693 (cm^{-1}); HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{15}\text{BrNO}_3\text{S}[\text{M}+\text{H}]^+$: 391.9951, found 391.9948.

7-chloro-4-methoxy-2-tosylquinoline (3ra)




^1H NMR (400 MHz, CDCl_3): δ = 8.13 (d, J = 9.2 Hz, 1 H), 8.06 (d, J = 2.0 Hz, 1 H), 8.00 (d, J = 8.8 Hz, 2 H), 7.58 (s, 1 H), 7.52 (dd, J_1 = 8.8 Hz, J_2 = 2.0 Hz, 1 H), 7.34 (d, J = 8.0 Hz, 1 H), 4.15 (s, 3 H), 2.42 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 164.4, 160.9, 148.7, 144.9, 137.2, 135.6, 129.7, 129.2, 128.9, 128.7, 123.4, 120.0, 97.1, 56.7, 21.7; IR (in KBr): ν = 2924, 1517, 1415, 1331, 1154, 1116, 819, 694 (cm^{-1}); HRMS (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{15}\text{ClNO}_3\text{S}[\text{M}+\text{H}]^+$: 348.0456, found 348.0452.

2-(phenylsulfonyl)quinoline (3ab)^d



^1H NMR (400 MHz, CDCl_3): δ = 8.39 (d, J = 8.8 Hz, 1 H), 8.23 – 8.14 (m, 4 H), 7.88 (d, J = 8.4 Hz, 1 H), 7.81 – 7.77 (m, 1 H), 7.68 – 7.65 (m, 1 H), 7.61 – 7.59 (m, 1 H), 7.56 – 7.52 (m, 2 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 158.1, 147.4, 139.1, 138.7, 133.7, 131.0, 130.4, 129.2, 129.1, 129.0, 128.8, 127.7, 117.7.


2-((4-(tert-butyl)phenyl)sulfonyl)quinoline (3ac)^d



^1H NMR (400 MHz, CDCl_3): δ = 8.37 (d, J = 8.8 Hz, 1 H), 8.20 (d, J = 8.8 Hz, 2 H), 8.06 (d, J = 8.8 Hz, 2 H), 7.87 (d, J = 8.4 Hz, 1 H), 7.81 – 7.70 (m, 1 H), 7.68 – 7.64 (m, 1 H), 7.54 (d, J = 8.8 Hz, 2 H), 1.31 (s, 9 H); ^{13}C


NMR (100 MHz, CDCl₃): δ = 158.4, 157.7, 147.5, 138.6, 136.1, 130.9, 130.5, 129.1, 128.9, 128.8, 127.7, 126.2, 117.8, 35.2, 31.0.

2-((4-methoxyphenyl)sulfonyl)quinoline (3ad)⁶




¹H NMR (400 MHz, CDCl₃): δ = 8.35 (d, J = 8.0 Hz, 1 H), 8.19 – 8.15 (m, 2 H), 8.07 (d, J = 8.8 Hz, 2 H), 7.86 (d, J = 8.0 Hz, 1 H), 7.77 (t, J = 7.6 Hz, 1 H), 7.64 (t, J = 7.6 Hz, 1 H), 6.99 (d, J = 8.8 Hz, 2 H), 3.84 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 163.9, 158.6, 147.4, 138.6, 131.2, 130.9, 130.5, 130.3, 129.0, 128.7, 127.6, 117.5, 114.3, 55.6.

2-((1,1'-biphenyl)-4-ylsulfonyl)quinoline (3ae)³




¹H NMR (400 MHz, CDCl₃): δ = 8.40 (d, J = 8.8 Hz, 1 H), 8.25 (d, J = 8.4 Hz, 1 H), 8.23 – 8.19 (m, 3 H), 7.89 (d, J = 8.4 Hz, 1 H), 7.82 – 7.78 (m, 1 H), 7.75 – 7.73 (m, 2 H), 7.69 – 7.65 (m, 1 H), 7.58 – 7.56 (m, 2 H), 7.47 – 7.38 (m, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 158.2, 147.5, 146.7, 139.2, 138.8, 137.6, 131.0, 130.4, 129.6, 129.2, 129.0, 128.9, 128.6, 127.7, 127.7, 127.4, 117.7.

2-((4-fluorophenyl)sulfonyl)quinoline (3af)³




¹H NMR (400 MHz, CDCl₃): δ = 8.46 (d, J = 8.8 Hz, 1 H), 8.28 – 8.20 (m, 4 H), 7.95 (dd, J_1 = 8.4 Hz, J_2 = 0.8 Hz, 1 H), 7.88 - 7.84 (m, 1 H), 7.75 – 7.71 (m, 1 H), 7.33 – 7.26 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃): δ = 165.9 (J_{C-F} = 254.5 Hz), 157.9, 147.4, 138.8, 134.9, 132.0 (J_{C-F} = 9.5 Hz), 131.1, 130.3, 129.3, 128.8, 127.7, 117.4, 116.4 (J_{C-F} = 22.6 Hz); ¹⁹F NMR (376 MHz, CDCl₃): δ = - 103.4.

2-((4-chlorophenyl)sulfonyl)quinoline (3ag)¹⁰




^1H NMR (400 MHz, CDCl_3): δ = 8.40 (d, J = 8.4 Hz, 1 H), 8.20 (d, J = 8.4 Hz, 1 H), 8.15 (dd, J_1 = 8.8 Hz, J_2 = 0.8 Hz, 1 H), 8.10 – 8.06 (m, 2 H), 7.89 (dd, J_1 = 8.4 Hz, J_2 = 1.2 Hz, 1 H), 7.82 – 7.78 (m, 1 H), 7.69 – 7.65 (m, 1 H), 7.52 – 7.49 (m, 2 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 157.7, 147.4, 140.5, 138.9, 137.4, 131.1, 130.5, 130.3, 129.4, 129.3, 128.9, 127.7, 117.5.

2-((4-bromophenyl)sulfonyl)quinoline (3ah)⁶




^1H NMR (400 MHz, CDCl_3): δ = 8.40 (d, J = 8.8 Hz, 1 H), 8.20 (d, J = 8.4 Hz, 1 H), 8.15 (d, J = 8.4 Hz, 1 H), 8.00 (d, J = 8.8 Hz, 2 H), 7.89 (d, J = 8.0 Hz, 1 H), 7.80 (t, J = 8.0 Hz, 1 H), 7.69 – 7.67 (m, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 157.7, 147.4, 138.9, 138.0, 132.4, 131.1, 130.6, 130.3, 129.4, 129.2, 128.9, 127.7, 117.5.

2-((4-(trifluoromethyl)phenyl)sulfonyl)quinoline (3ai)³



^1H NMR (400 MHz, CDCl_3): δ = 8.42 (d, J = 8.4 Hz, 1 H), 8.29 (d, J = 8.4 Hz, 2 H), 8.23 (d, J = 8.8 Hz, 1 H), 8.14 (d, J = 8.4 Hz, 1 H), 7.90 (d, J = 8.0 Hz, 1 H), 7.82 – 7.78 (m, 3 H), 7.70 – 7.66 (m, 1 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 157.3, 147.4, 142.6, 139.0, 135.2 ($J_{\text{C-F}}$ = 32.8), 131.2, 130.3, 129.7, 129.5, 128.9, 127.7, 126.1 ($J_{\text{C-F}}$ = 3.7), 123.1 ($J_{\text{C-F}}$ = 271.2), 117.5; ^{19}F NMR (376 MHz, CDCl_3): δ = - 63.2.


ethyl 4-(quinolin-2-ylsulfonyl)benzoate (3aj)⁵



^1H NMR (400 MHz, CDCl_3): δ = 8.41 (d, J = 8.4 Hz, 1 H), 8.24 – 8.18 (m, 5 H), 8.14 (d, J = 8.4 Hz, 1 H), 7.89 (d, J = 8.0 Hz, 1 H), 7.82 – 7.78 (m, 1 H), 7.69 – 7.66 (m, 1 H), 4.39 (q, J = 7.2 Hz, 2 H), 1.39 (t, J = 7.2 Hz, 3 H); ^{13}C


NMR (100 MHz, CDCl₃): δ = 165.1, 157.6, 147.5, 142.8, 138.9, 135.1, 131.2, 130.4, 130.1, 129.4, 129.1, 128.9, 127.7, 117.6, 61.7, 14.2.

2-((3-bromophenyl)sulfonyl)quinoline (3ak)¹¹




¹H NMR (400 MHz, CDCl₃): δ = 8.41 (d, J = 8.4 Hz, 1 H), 8.28 (t, J = 2.0 Hz, 1 H), 8.22 (d, J = 8.8 Hz, 1 H), 8.18 (d, J = 8.4 Hz, 1 H), 8.10 – 8.07 (m, 1 H), 7.90 (d, J = 8.4 Hz, 1 H), 7.83 – 7.79 (m, 1 H), 7.74 – 7.67 (m, 2 H), 7.40 (t, J = 8.0 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃): δ = 157.5, 147.5, 140.9, 138.9, 136.8, 131.8, 131.2, 130.5, 130.4, 129.4, 128.9, 127.7, 127.7, 123.0, 117.6.

2-(*o*-tolylsulfonyl)quinoline (3al)⁶



¹H NMR (400 MHz, CDCl₃): δ = 8.38 (d, J = 8.4 Hz, 1 H), 8.31 (dd, J_1 = 8.0 Hz, J_2 = 1.6 Hz, 1 H), 8.17 (d, J = 8.4 Hz, 1 H), 8.10 (d, J = 8.4 Hz, 1 H), 7.88 (dd, J_1 = 8.0 Hz, J_2 = 1.2 Hz, 1 H), 7.78 – 7.75 (m, 1 H), 7.65 – 7.63 (m, 1 H), 7.51 – 7.47 (m, 1 H), 7.41 (t, J = 7.6 Hz, 1 H), 7.24 (d, J = 7.2 Hz, 1 H), 2.56 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 158.1, 147.1, 139.1, 138.6, 137.1, 133.9, 132.4, 130.9, 130.6, 130.3, 129.1, 128.8, 127.7, 126.3, 117.7, 20.7.


2-((3,4-difluorophenyl)sulfonyl)quinoline (3am)



¹H NMR (400 MHz, CDCl₃): δ = 8.41 (d, J = 8.0 Hz, 1 H), 8.19 (d, J = 8.4 Hz, 1 H), 8.13 (dd, J_1 = 8.4 Hz, J_2 = 1.2 Hz, 1 H), 8.02 – 7.97 (m, 1 H), 7.94 – 7.88 (m, 2 H), 7.82 – 7.77 (m, 1 H), 7.69 – 7.65 (m, 1 H), 7.35 – 7.29 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃): δ = 157.3, 153.9 (dd, J_1 = 257.4 Hz, J_2 = 12.4 Hz, 1C), 150.1 (dd, J_1 = 253.8 Hz, J_2 = 13.9 Hz, 1C), 147.3, 139.0, 131.2, 130.2, 129.4, 128.9, 127.7, 126.4 (dd, J_1 = 8.0 Hz, J_2 = 4.3 Hz, 1C), 119.0 (dd, J_1 = 19.7 Hz, J_2 = 2.2 Hz, 1C), 118.3, 118.1, 117.3; ¹⁹F NMR (376 MHz, CDCl₃): δ = -127.6 (d, J = 20.3, 1F), -133.6 (d, J = 20.3, 1F); IR (in KBr): ν = 3038, 1932, 1670, 1497, 1327, 1268, 907, 833, 693 (cm⁻¹); HRMS (ESI)


m/z calcd. for C₁₅H₁₀F₂NO₂S[M+H]⁺ : 306.0395, found 306.0393.

2-((3,5-dichlorophenyl)sulfonyl)quinolone (3an)




¹H NMR (400 MHz, CDCl₃): δ = 8.42 (dd, *J*₁ = 8.8 Hz, *J*₂ = 0.4 Hz, 1 H), 8.20 (d, *J* = 8.8 Hz, 1 H), 8.16 (dd, *J*₁ = 8.4 Hz, *J*₂ = 0.8 Hz, 1 H), 8.01 (d, *J* = 1.6 Hz, 2 H), 7.90 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1 H), 7.82 – 7.79 (m, 1 H), 7.71 – 7.67 (m, 1 H), 7.54 (t, *J* = 2.0 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃): δ = 156.9, 147.4, 141.9, 139.1, 135.9, 133.7, 131.3, 130.3, 129.6, 129.0, 127.7, 127.4, 117.5; IR (in KBr): ν = 2924, 1517, 1415, 1331, 1154, 1116, 909, 819, 694 (cm⁻¹); HRMS (ESI) m/z calcd. for C₁₅H₁₀Cl₂NO₂S[M+H]⁺ : 337.9804, found 337.9798.

2-((3-chloro-4-fluorophenyl)sulfonyl)quinoline (3ao)⁵



¹H NMR (400 MHz, CDCl₃): δ = 8.41 (d, *J* = 8.4 Hz, 1 H), 8.23 – 8.19 (m, 2 H), 8.14 (d, *J* = 8.4 Hz, 1 H), 8.08 – 8.04 (m, 1 H), 7.90 (d, *J* = 8.4 Hz, 1 H), 7.83 – 7.87 (m, 1 H), 7.70 – 7.66 (m, 1 H), 7.30 (t, *J* = 8.4 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃): δ = 161.3 (*J*_{C-F} = 256.6 Hz), 157.4, 147.4, 139.0, 135.9 (*J*_{C-F} = 3.6 Hz), 132.0 (*J*_{C-F} = 1.5 Hz), 131.2, 130.2, 129.7 (*J*_{C-F} = 8.8 Hz), 129.5, 128.9, 127.7, 122.5 (*J*_{C-F} = 18 Hz), 117.5, 117.4 (*J*_{C-F} = 21.8 Hz), 117.4; ¹⁹F NMR (376 MHz, CDCl₃): δ = - 105.5.


2-((3-fluoro-4-methoxyphenyl)sulfonyl)quinolone (3ap)



¹H NMR (400 MHz, CDCl₃): δ = 8.38 (d, *J* = 8.0 Hz, 1 H), 8.19 – 8.15 (m, 2 H), 7.93 – 7.77 (m, 4 H), 7.68 – 7.64 (m, 1 H), 7.08 – 7.04 (m, 1 H), 3.92 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ = 158.0, 151.6 (d, *J*_{C-F} = 250.8), 152.4 (d, *J*_{C-F} = 10.2), 147.4, 138.8, 131.0, 130.3, 129.2, 128.8, 127.7, 126.5 (d, *J*_{C-F} = 3.6), 117.1, 117.4, 116.9, 112.8 (d, *J*_{C-F} = 2.2), 56.4; ¹⁹F NMR (376 MHz, CDCl₃): δ = - 131.8; IR (in KBr): ν = 3421, 1600, 1504, 1430,


1329, 1283, 1165, 1010, 819, 686(cm^{-1}); HRMS (ESI) m/z calcd. for $\text{C}_{16}\text{H}_{13}\text{FNO}_3\text{S}[\text{M}+\text{H}]^+$: 318.0595, found 318.0598.

2-(naphthalen-2-ylsulfonyl)quinoline (3aq)⁴



^1H NMR (400 MHz, CDCl_3): δ = 8.75 (d, J = 2.0 Hz, 1 H), 8.38 (d, J = 8.4 Hz, 1 H), 8.27 (d, J = 8.4 Hz, 1 H), 8.16 (d, J = 8.4 Hz, 1 H), 8.08 (dd, J_1 = 8.4 Hz, J_2 = 1.6 Hz, 1 H), 8.00 (d, J = 8.0 Hz, 1 H), 7.95 (d, J = 8.4 Hz, 1 H), 7.88 – 7.85 (m, 2 H), 7.78 – 7.74 (m, 1 H), 7.66 – 7.57 (m, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 158.1, 147.4, 138.7, 136.0, 135.3, 132.1, 131.0, 130.8, 130.3, 129.5, 129.3, 129.2, 128.8, 127.9, 127.6, 127.5, 123.7, 117.8.

heptan-2-yl 2-((5-chloro-2-tosylquinolin-8-yl)oxy)acetate (3sa)





^1H NMR (400 MHz, CDCl_3): δ = 8.74 (d, J = 8.8 Hz, 1 H), 8.30 (d, J = 8.8 Hz, 1 H), 8.06 (d, J = 8.4 Hz, 2 H), 7.60 (d, J = 8.4 Hz, 1 H), 7.35 (d, J = 8.0 Hz, 2 H), 7.11 (d, J = 8.04 Hz, 1 H), 5.04 – 4.99 (m, 1 H), 4.85 (s, 2 H), 2.41 (s, 3 H), 1.51 – 1.46 (m, 2 H), 1.25 – 1.23 (s, 9 H), 0.86 (t, J = 7.2 Hz, 3 H); ^{13}C NMR (100 MHz, CDCl_3): δ = 158.1, 153.5, 145.0, 140.3, 136.1, 135.7, 129.8, 129.4, 128.9, 127.8, 124.0, 118.6, 114.6, 72.6, 67.8, 35.8, 31.5, 25.0, 22.5, 21.7, 19.9, 13.9; IR (in KBr): ν = 3425, 2927, 1765, 1570, 1415, 1318, 1209, 1114, 813, 696 (cm^{-1}); HRMS (ESI) m/z calcd. for $\text{C}_{25}\text{H}_{29}\text{ClNO}_5\text{S}[\text{M}+\text{H}]^+$: 490.1449, found 490.1445.

4. References



1. G. Li, C. Jia and K. Sun, *Org. Lett.*, 2013, **15**, 5198-5201.
2. R. Wang, Z. Zeng, C. Chen, N. Yi, J. Jiang, Z. Cao, W. Deng and J. Xiang, *Org. Biomol. Chem.*, 2016, **14**, 5317-5321.
3. B. Du, P. Qian, Y. Wang, H. Mei, J. Han and Y. Pan, *Org. Lett.*, 2016, **18**, 4144-4147.
4. K. Sun, X.-L. Chen, X. Li, L.-B. Qu, W.-Z. Bi, X. Chen, H.-L. Ma, S.-T. Zhang, B.-W. Han, Y.-F. Zhao and C.-J. Li, *Chem. Commun.*, 2015, **51**, 12111-12114.
5. L.-Y. Xie, Y.-J. Li, J. Qu, Y. Duan, J. Hu, K.-J. Liu, Z. Cao and W.-M. He, *Green Chem.*, 2017, **19**, 5642-5646.
6. L. Sumunnee, C. Buathongjan, C. Pimpasri and S. Yotphan, *Eur. J. Org. Chem.*, 2017, **2017**, 1025-1032.
7. Y. Su, X. Zhou, C. He, W. Zhang, X. Ling and X. Xiao, *J. Org. Chem.*, 2016, **81**, 4981-4987.
8. P. Bao, L. Wang, Q. Liu, D. Yang, H. Wang, X. Zhao, H. Yue and W. Wei, *Tetrahedron Lett.*, 2019, **60**, 214-218.
9. L.-Y. Xie, S. Peng, F. Liu, G.-R. Chen, W. Xia, X. Yu, W.-F. Li, Z. Cao and W.-M. He, *Org. Chem. Front.*, 2018, **5**, 2604-2609.
10. F. Wen - Kai, S. Kai, Q. Chen, C. Xiao - Lan, Q. Ling - Bo, B. Wen - Zhu and Z. Yu - Fen, *Asian. J. Org. Chem.*, 2017, **6**, 492-495.
11. H.-Y. Lee, C.-Y. Chang, C.-J. Su, H.-L. Huang, S. Mehndiratta, Y.-H. Chao, C.-M. Hsu, S. Kumar, T.-Y. Sung, Y.-Z. Huang, Y.-H. Li, C.-R. Yang and J.-P. Liou, *Eur. J. Med. Chem.*, 2016, **122**, 92-101.

5. ^1H and ^{13}C NMR spectra of products



2-tosylquinoline (3aa)





3-methyl-2-tosylquinoline (3ba)





4-methyl-2-tosylquinoline (3ca)





5-methyl-2-tosylquinoline (3da)





6-methyl-2-tosylquinoline (3ea)





7-methyl-2-tosylquinoline (3fa)





8-methyl-2-tosylquinoline (3ga)





6-methoxy-2-tosylquinoline (3ha)





6-fluoro-2-tosylquinoline (3ia)





6-chloro-2-tosylquinoline (3ja)





4-chloro-2-tosylquinoline (3ka)





3-bromo-2-tosylquinoline (31a)





5-bromo-2-tosylquinoline (3ma)





6-bromo-2-tosylquinoline (3na)





8-bromo-2-tosylquinoline (30a)





8-(4-bromophenyl)-2-tosylquinoline (3pa)





6-bromo-4-methoxy-2-tosylquinoline (3qa)





7-chloro-4-methoxy-2-tosylquinoline (3ra)





2-(phenylsulfonyl)quinoline (3ab)





2-((4-*tert*-butyl)phenyl)sulfonylquinoline (3ac)




2-((4-methoxyphenyl)sulfonyl)quinoline (3ad)




2-([1,1'-biphenyl]-4-ylsulfonyl)quinolone (3ac)





2-((4-fluorophenyl)sulfonyl)quinoline (3af)





2-((4-chlorophenyl)sulfonyl)quinoline (3ag)





2-((4-bromophenyl)sulfonyl)quinoline (3ah)





2-((4-(trifluoromethyl)phenyl)sulfonyl)quinoline (3ai)





ethyl 4-(quinolin-2-ylsulfonyl)benzoate (3aj)





2-((3-bromophenyl)sulfonyl)quinoline (3ak)





2-(*o*-tolylsulfonyl)quinoline (3a)




2-((3,4-difluorophenyl)sulfonyl)quinolone (3am)





2-((3,5-dichlorophenyl)sulfonyl)quinolone (3an)





2-((3-chloro-4-fluorophenyl)sulfonyl)quinoline (3ao)



2-((3-fluoro-4-methoxyphenyl)sulfonyl)quinolone (3ap)



2-(naphthalen-2-ylsulfonyl)quinoline (3aq)



heptan-2-yl 2-((5-chloro-2-tosylquinolin-8-yl)oxy)acetate (3sa)

